PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22221095-0	2012	Contribution of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to hepatic uptake of nateglinide, and the prediction of drug-drug interactions via these transporters.	Nateglinide	99-110	solute carrier organic anion transporter family member 1B1	Homo sapiens	16-65	
30135178-6	2018	All but two drugs showed substrate affinity to OAT2, whereas four (bromfenac, entacapone, fluorescein, and nateglinide) also showed OATP1B1 activity in transfected cells.	Nateglinide	107-118	solute carrier organic anion transporter family member 1B1	Homo sapiens	132-139	
22842957-0	2013	Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.	Nateglinide	91-102	solute carrier organic anion transporter family member 1B1	Homo sapiens	21-28	
22842957-2	2013	Our objective was to assess the association between CYP2C9 and SLCO1B1 polymorphisms and the metabolism of nateglinide in healthy Chinese male volunteers.	Nateglinide	107-118	solute carrier organic anion transporter family member 1B1	Homo sapiens	63-70	
22842957-7	2013	CONCLUSIONS: Both SLCO1B1 521 T>C and the CYP2C9*3 polymorphisms can significantly affect the pharmacokinetics of nateglinide, but they could only partially explain the interindividual variability of plasma concentration of nateglinide.	Nateglinide	117-128	solute carrier organic anion transporter family member 1B1	Homo sapiens	18-25	
22221095-9	2012	CONCLUSIONS: OATP1B1 and OATP1B3 may have contributed to the hepatic uptake of nateglinide, but the possibility of drug-drug interactions appeared to be low.	Nateglinide	79-90	solute carrier organic anion transporter family member 1B1	Homo sapiens	13-20	
22221095-1	2012	OBJECTIVES: We have investigated the contributions of organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 to the hepatic uptake of nateglinide, and the possibility of drug-drug interactions via these transporters.	Nateglinide	141-152	solute carrier organic anion transporter family member 1B1	Homo sapiens	54-103	
22221095-5	2012	A certain increase in uptake was observed in the examination using transporter-expressing HEK293 cells, indicating contributions of OATP1B1 and OATP1B3 to hepatic nateglinide uptake.	Nateglinide	163-174	solute carrier organic anion transporter family member 1B1	Homo sapiens	132-139	
22221095-6	2012	The 50% inhibitory concentration (IC50) values of nateglinide using cryopreserved human hepatocytes for uptake of estrone 3-sulfate (substrate of OATP1B1), and cholecystokinin octapeptide (substrate of OATP1B3) were 168 and 17.4 micromol/l, respectively.	Nateglinide	50-61	solute carrier organic anion transporter family member 1B1	Homo sapiens	146-153	
22221095-8	2012	The calculated 1 + I(in,max,u) /IC50 values for inhibition of OATP1B1 and OATP1B3 by nateglinide, and the inhibition of saturable uptake of nateglinide by ciclosporin, were all close to 1, indicating a low clinical risk of drug-drug interaction with nateglinide taken up via OATP1B1 and OATP1B3.	Nateglinide	85-96	solute carrier organic anion transporter family member 1B1	Homo sapiens	62-69	
20406215-8	2010	In Chinese individuals, the SLCO1B1 c.521C allele has been associated with increased plasma concentrations of nateglinide, but the association could not be replicated in Caucasians.	Nateglinide	110-121	solute carrier organic anion transporter family member 1B1	Homo sapiens	28-35	
18187595-0	2008	Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.	Nateglinide	106-117	solute carrier organic anion transporter family member 1B1	Homo sapiens	21-28	
18854776-2	2008	The aim of this study was to investigate whether the SLCO1B1*1B haplotype affects the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.	Nateglinide	143-154	solute carrier organic anion transporter family member 1B1	Homo sapiens	53-60	
18854776-6	2008	The Cmax of nateglinide occurred earlier in the SLCO1B1*1B/*1B participants than in the SLCO1B1*1A/*1A participants (P=0.004), but no differences were seen in the other pharmacokinetic variables of nateglinide.	Nateglinide	12-23	solute carrier organic anion transporter family member 1B1	Homo sapiens	48-55	
18854776-6	2008	The Cmax of nateglinide occurred earlier in the SLCO1B1*1B/*1B participants than in the SLCO1B1*1A/*1A participants (P=0.004), but no differences were seen in the other pharmacokinetic variables of nateglinide.	Nateglinide	12-23	solute carrier organic anion transporter family member 1B1	Homo sapiens	88-95	
18854776-7	2008	CONCLUSION: The SLCO1B1*1B/*1B genotype is associated with reduced plasma concentrations of repaglinide, consistent with an enhanced hepatic uptake by OATP1B1, but has limited effects on the pharmacokinetics of nateglinide.	Nateglinide	211-222	solute carrier organic anion transporter family member 1B1	Homo sapiens	16-23	
16796707-10	2006	CONCLUSIONS: Our results suggest that OATP1B1-mediated hepatic uptake of nateglinide may be the prior step for its metabolism and elimination.	Nateglinide	73-84	solute carrier organic anion transporter family member 1B1	Homo sapiens	38-45	
16796707-0	2006	Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.	Nateglinide	66-77	solute carrier organic anion transporter family member 1B1	Homo sapiens	10-17	
16796707-3	2006	Our objective was to assess the association between single nucleotide polymorphisms (SNPs) of SLCO1B1 and the pharmacokinetics of nateglinide.	Nateglinide	130-141	solute carrier organic anion transporter family member 1B1	Homo sapiens	94-101